All Posts By

Ashley Brod

Software as a Drug

By | NEWS | No Comments

What if your spouse were a borderline Type 2 diabetic?  If you had the money, you could hire someone to follow her or him around the clock, sort of like a glorified personal trainer.  Your spouse would make sure he or she took a daily mile-long walk, did some weight training to build muscle mass and would stop you from eating ice cream or cake or drinking a glass of wine. Read More

Gamma Medica Announces New Partnership in the Fight Against Breast Cancer with Henry Ford Health System LP

By | NEWS | No Comments

WEST BLOOMFIELD, Michigan & SALEM, N.H. – (Nov. 3, 2016 ) Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that Henry Ford Health System has purchased Gamma Medica’s LumaGEM Molecular Breast Imaging system. The system is set to be installed by the end of 2016 at Henry Ford West Bloomfield Hospital. The MBI technology will be offered as a secondary screening and diagnostic tool following X-ray mammography, particularly for women with dense breast tissue. This proven imaging modality will help improve cancer detection in women who are at greater risk of developing breast cancer. Read More

Dallas-Based HealthMine, a Psilos Portfolio Company, Featured in 2016 Outlook Report

By | NEWS | No Comments

NEW YORK, NY–(Marketwired – Oct 6, 2016) – Psilos Group, in its seventh annual OUTLOOK outlining major emerging healthcare trends, says digital therapeutics is a $6 billion market opportunity by 2021. Digital therapeutics — “software as a drug” — deploys software modules as an enhancement, or even a substitute, to a drug. It is poised to become a critical component of digital health and to substantially improve the efficiency of American healthcare. Read More

Psilos Group: Digital Therapeutics — “Software as a Drug” — Is a $6 Billion Potential Market Opportunity Says 2016 Outlook Report

By | NEWS | No Comments
Utilizing Software Modules as an Enhancement to Pharmaceuticals for Chronic Conditions Is Poised to Be Critical Component of Digital Healthcare

NEW YORK, NY — (Marketwired) — 10/06/16 — Psilos Group, in its seventh annual OUTLOOK outlining major emerging healthcare trends, says digital therapeutics is a $6 billion market opportunity by 2021. Digital therapeutics — “software as a drug” — deploys software modules as an enhancement, or even a substitute, to a drug. It is poised to become a critical component of digital health and to substantially improve the efficiency of American healthcare.

Read More

Yahoo! Finance Features 2016 Psilos Outlook Report

By | Uncategorized | No Comments

Psilos, a prominent digital health venture and growth stage investment firm, says digital therapeutics improves health outcomes by addressing chronic conditions through behavioral changes, before they become worse. The new generation of digital therapeutics is demonstrating clinical efficacy by marrying the latest developments in behavioral economics, smartphones, game-ification, biometric sensors, data analytics and artificial intelligence. The long-term goal of digital therapeutics is to bend the healthcare cost curve. Read More

The Arizona Republic Features 2016 Psilos Outlook Report

By | NEWS | No Comments

NEW YORK, NY — (Marketwired) — 10/06/16 — Psilos Group, in its seventh annualOUTLOOK outlining major emerging healthcare trends, says digital therapeutics is a $6 billion market opportunity by 2021. Digital therapeutics — “software as a drug” — deploys software modules as an enhancement, or even a substitute, to a drug. It is poised to become a critical component of digital health and to substantially improve the efficiency of American healthcare. Read More

Breakthrough Clinical Study Confirms LumaGEM®’s Molecular Breast Imaging (MBI)’s High Cancer Detection Rate in Dense Breast Tissue Following Cancer-Negative Mammograms

By | NEWS | No Comments

SALEM, N.H.–(BUSINESS WIRE)–A breakthrough retrospective study in AJR’s August issue confirmed Gamma Medica’s molecular breast imaging (MBI) technology’s high incremental cancer detection rate of 7.7 cancers per thousand (7.7/1000) and overall clinical effectiveness as a secondary screening tool in finding 13 malignancies among 1,696 women with dense breast tissue following mammograms that read negative for cancer.1  Read More

The 2016 HealthMine Digital Health Report

By | NEWS | No Comments

The objective of the HealthMine Digital Health Report is
to give health plan sponsors (payers and employers) insight into
the adoption and impact of digital health tools.
Consumer use of digital health tools is growing rapidly. According
to research firm Accenture, using digital health tools in primary
care could save the US healthcare system $10 billion annually. As
the aging population and prevalence of chronic disease in America
grows, internet-connected health devices and applications can
help support primary and specialty healthcare.  Read More

Dr. Nathalie Johnson, M.D., FACS, Joins Gamma Medica’s Clinical Advisory Board

By | NEWS | No Comments

SALEM, N.H.–(BUSINESS WIRE)–Gamma Medica, a leader in molecular breast imaging technology (MBI), announced today that Dr. Nathalie Johnson, M.D., FACS, of the Legacy Cancer Institute and the Legacy Breast Health Centers in Portland, Oregon has agreed to join the organizations’ clinical advisory board, currently comprised of distinguished clinicians and thought leaders with expertise in women’s health technologies and diagnostic imaging. Dr. Johnson and the board will provide strategic and clinical advice as Gamma Medica continues commercialization and enhancements of its LumaGEM® Molecular Breast Imaging system. Read More

Gamma Medica Launches Be Certain Campaign to Educate Women on Dense Breast Tissue

By | NEWS | No Comments

SALEM, NH – May 5, 2016Gamma Medica, a leader in molecular breast imaging technology (MBI), announced today it has launched the Be Certain campaign, featuring a dedicated microsite as the cornerstone of an initiative to spread awareness on breast density. Today, about half of all women in the United States have dense breast tissue, making them four to five times[1] more likely to develop breast cancer. Traditional screening technology alone is not advanced enough to accurately detect cancerous tumors for these women who have a higher intrinsic risk of developing cancer during the course of their lifetime. Read More

Six reasons digital health is coming of age

By | NEWS | No Comments

Digital healthcare, a discipline with enormous potential to dramatically improve healthcare and healthcare delivery as we know it, is no longer an experiment or a novelty. It is a budding industry attracting not only major new players and consumers but, most important, investors – the key to ongoing adoption and growth. Read More

Southwest X-Ray LP Installs Gamma Medica’s LumaGEM® Molecular Breast Imaging System as a Secondary Screening and Diagnostic Tool for Women with Dense Breasts

By | NEWS | No Comments

EL PASO, TX and SALEM, NH – March 28, 2016Gamma Medica, a leader in molecular breast imaging technology (MBI), announced today that Southwest X-Ray, the leading outpatient services provider in El Paso, TX, has installed Gamma Medica’s LumaGEM Molecular Breast Imaging (MBI) system in its Gateway Blvd. West location. Southwest X-Ray will utilize the LumaGEM MBI system as a secondary diagnostic tool for inconclusive mammography screenings in patients with dense breast tissue. Read More

The digital healthcare tsunami

By | NEWS | No Comments

An emerging, ground-breaking trend, the convergence of the healthcare system with digital technology, is rippling across healthcare and providing compelling investment opportunities for astute investors, particularly in private markets. Best of all, it’s only in its early stages. Read More

Gamma Medica and Alpha Imaging Partner and Sign Distribution Agreement

By | NEWS | No Comments

Expanding the reach of Molecular Breast Imaging; a new standard of care in early breast cancer detection

WILLOUGHBY, OH and SALEM, NH – January 6, 2016 – Alpha Imaging, one of the largest independent sales and service providers of advanced medical imaging equipment, today announced that it has executed a distribution agreement with Gamma Medica, Inc. The agreement covers distribution of Gamma Medica’s LumaGEM Molecular Breast Imaging solution in the Midwest and Mid-Atlantic regions. Read More

Psilos VC: Digital Health Will Emerge as Top Performer in 2016

By | NEWS | No Comments

As 2015 winds down, it’s a good time to look into the crystal ball for one of the toughest industries to predict: healthcare.

We recently picked the brain of David Eichler, a managing partner with New York-based venture capital firm Psilos Group. Eichler (pictured) focuses on investments in digital health and medical device companies, and he currently is the board chair of Gamma Medica and Caregiver Services. Read More

Pink is The New Black; The Health Care Blog Op Ed by David Eichler

By | NEWS | No Comments

Pink is the new black this October, which marks the 30th anniversary of National Breast Cancer Awareness Month. NFL players are clad in bright pink shoes and wrist bands. American Airlines employees are wearing pink uniform accents and serving complimentary pink lemonade. Police departments across the country are patrolling in pink cruisers. It’s all for a great cause. The money and awareness raised through this campaign helps to fight an insidious disease that will kill more than 40,000 women in the U.S. this year. Read More

Marshfield Clinic Health System, Gamma Medica Partner to Create World’s First Mobile Molecular Breast Imaging Unit

By | NEWS | No Comments

Women throughout Wisconsin will now have access to a new standard of care in early breast cancer detection

MARSHFIELD, WI and SALEM, NH – October 27, 2015 – Marshfield Clinic Health System (MCHS) and Gamma Medica, Inc., today announced their partnership to install the LumaGEM® Molecular Breast Imaging (MBI) system on a new mobile medical unit, creating the world’s first mobile MBI service. Read More

Gamma Medica Receives CE Mark for LumaGEM® Molecular Breast Imaging System, a New Standard of Care in Breast Imaging

By | NEWS | No Comments

SALEM, N.H, – October 12, 2015 – Gamma Medica, Inc., a breast imaging medical device company, today announced the CE Mark approval allowing for the sale and distribution of the LumaGEM® Molecular Breast Imaging (MBI) system within the European Economic Area (EEA). Gamma Medica is finalizing distribution partners in strategic markets across the EEA. Read More

Breaking Health Podcast: Hosted by Stephen Krupa

By | NEWS | No Comments

Norwest Venture Partners General Partner Robert Mittendorff, MD, and Breaking Health Host Steve Krupa of Psilos Group bring their considerable experiences to bear. Krupa delves into Mittendorff’s ability to balance practicing medicine with identifying game-changing new digital health technologies for one of the leading investors in digital health. Mittendorff also discusses the highlights he sees in the coming Digital Healthcare Innovation Summit including Digital Therapeutics, Population Health, and the Rise of the Consumer. Read More

Gamma Medica Bolsters Executive Team to Support the Fight Against Breast Cancer with Focus on Growth and Commercialization of Molecular Breast Imaging

By | NEWS | No Comments

Salem, N.H., June 8, 2015Gamma Medica, a leader in molecular breast imaging (MBI) technology, announced today that Philip M. Croxford has been appointed as Chief Executive Officer. The Company also named Scott Headland as its new Vice President of Sales. These executive changes align with Gamma Medica’s focus on commercializing its unique breast imaging technology for improved cancer detection in the 40 percent of women with dense breast tissue. Gamma Medica’s former CEO, Jim Calandra, has left the company to pursue other business opportunities. Read More